Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 127Neoplasm Metastasis 14Neoplasms 9Advanced Breast Cancer 6Endometrial Neoplasms 5Recurrence 4Hereditary Sensory and Autonomic Neuropathies 4Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Ovarian Neoplasms 3Neoplasms, Hormone-Dependent 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Lobular 3Carcinoma, Ductal, Breast 3Squamous Cell Carcinoma of Head and Neck 2Polycystic Ovary Syndrome 2Osteoporosis 2Neoplasms by Site 2Lymphoma, Non-Hodgkin 2Head and Neck Neoplasms 2HR+/HER2- Breast Cancer 2Breast Neoplasms, Male 2Breast Diseases 2Bone Diseases, Metabolic 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Small Cell Lung Carcinoma 1Osteitis Deformans 1Multiple Endocrine Neoplasia Type 1 1Mesothelioma, Malignant 1

Interventions

ON123300 1Letrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Endometrioid Endometrial Cancer × Letrozole × Clear all
NCT05705505 2023-12-12

Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies

Traws Pharma, Inc.

Phase 1/2 Unknown
60 enrolled
Gynecologic

Endometrioid Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡